Cargando…

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma

BACKGROUND: Reducing diagnostic delays in cancer has been a major interest worldwide; however, the literature on diagnostic delays in lymphoma remains scarce. Diffuse large B‐cell lymphoma (DLBCL) is the most common non‐Hodgkin's lymphoma. We aimed to determine whether certain structural factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zurko, Joanna C., Wade, Raymond C., Mehta, Amitkumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488145/ https://www.ncbi.nlm.nih.gov/pubmed/30884208 http://dx.doi.org/10.1002/cam4.2009

Ejemplares similares

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
por: Zurko, Joanna, et al.
Publicado: (2018)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B‐cell lymphoma
por: Tian, Tian, et al.
Publicado: (2020)

Associations between race and survival in pediatric patients with diffuse large B‐cell lymphoma
por: Khullar, Karishma, et al.
Publicado: (2021)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B‐cell lymphoma
por: Ma, Xiao‐bo, et al.
Publicado: (2018)

Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
por: Xie, Yongzhi, et al.
Publicado: (2021)

Machine learning‐based classification of diffuse large B‐cell lymphoma patients by eight gene expression profiles
por: Zhao, Shuangtao, et al.
Publicado: (2016)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
por: Chambers, Pinkie, et al.
Publicado: (2021)

Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017)

Outcomes after (90)Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
por: Auger-Quittet, Sophie, et al.
Publicado: (2014)

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma
por: Li, Xiaoqian, et al.
Publicado: (2019)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma
por: Kwanhian, Wiyada, et al.
Publicado: (2012)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B‐cell aggregates in the bone marrow of patients with diffuse large B‐cell lymphoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway
por: Hu, Tonglin, et al.
Publicado: (2020)

Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B‐cell lymphoma cells and their association with clinical features
por: Kobayashi, Kyoko, et al.
Publicado: (2016)

PD‐1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma
por: Zhang, Wei, et al.
Publicado: (2016)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy
por: Mizuno, Yoshimi, et al.
Publicado: (2018)

The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019)

Cutaneous diffuse large B‐cell lymphoma
por: Duarte Ribeiro, Filipa, et al.
Publicado: (2017)

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
por: Autio, Matias, et al.
Publicado: (2022)

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes
por: Zhao, Shuangtao, et al.
Publicado: (2016)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Diffuse large B‐cell lymphoma mimicking cardiac amyloidosis
por: Lau, Lawrence, et al.
Publicado: (2017)

Bone marrow biopsy superiority over PET/CT in predicting progression‐free survival in a homogeneously‐treated cohort of diffuse large B‐cell lymphoma
por: Chen‐Liang, Tzu‐Hua, et al.
Publicado: (2017)

A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
por: Zhang, Yi‐Yang, et al.
Publicado: (2019)

The beneficial effect of Escalated‐R‐CHOP‐21 for the treatment of diffuse large B‐cell lymphoma in elderly male patients: A propensity‐matched cohort study
por: He, Hai‐Xia, et al.
Publicado: (2021)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B‐cell lymphoma
por: Dong, Huan, et al.
Publicado: (2020)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_khftoqn9iog4jsd165k5f1dic7